150 related articles for article (PubMed ID: 8343175)
1. Direct electrochemical measurement of nitric oxide released from human platelets.
Malinski T; Radomski MW; Taha Z; Moncada S
Biochem Biophys Res Commun; 1993 Jul; 194(2):960-5. PubMed ID: 8343175
[TBL] [Abstract][Full Text] [Related]
2. Studies on the importance of the proposed release of nitric oxide from platelets.
Mollace V; Salvemini D; Vane J
Thromb Res; 1991 Dec; 64(5):533-42. PubMed ID: 1725563
[TBL] [Abstract][Full Text] [Related]
3. Direct measurement of nitric oxide production in platelets: relationship with cytosolic Ca2+ concentration.
Lantoine F; Brunet A; Bedioui F; Devynck J; Devynck MA
Biochem Biophys Res Commun; 1995 Oct; 215(3):842-8. PubMed ID: 7488050
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the L-arginine:nitric oxide pathway in human platelets.
Radomski MW; Palmer RM; Moncada S
Br J Pharmacol; 1990 Oct; 101(2):325-8. PubMed ID: 1701676
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory effects of endogenous L-arginine analogues on nitric oxide synthesis in platelets: role in platelet hyperaggregability in hypertension.
de Meirelles LR; Mendes-Ribeiro AC; Santoro MM; Mendes MA; da Silva MN; Mann GE; Brunini TM
Clin Exp Pharmacol Physiol; 2007 Dec; 34(12):1267-71. PubMed ID: 17973865
[TBL] [Abstract][Full Text] [Related]
6. The calcium modulator nifedipine exerts its antiaggregatory property via a nitric oxide mediated process.
Berkels R; Klaus W; Boller M; Rösen R
Thromb Haemost; 1994 Aug; 72(2):309-12. PubMed ID: 7831670
[TBL] [Abstract][Full Text] [Related]
7. Carbon monoxide released by CORM-3 inhibits human platelets by a mechanism independent of soluble guanylate cyclase.
Chlopicki S; Olszanecki R; Marcinkiewicz E; Lomnicka M; Motterlini R
Cardiovasc Res; 2006 Jul; 71(2):393-401. PubMed ID: 16713591
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of l-arginine transport in platelets by asymmetric dimethylarginine and N-monomethyl-l-arginine: effects of arterial hypertension.
Brunini T; Moss M; Siqueira M; Meirelles L; Rozentul A; Mann G; Ellory J; Soares de Moura R; Mendes-Ribeiro A
Clin Exp Pharmacol Physiol; 2004 Oct; 31(10):738-40. PubMed ID: 15554917
[TBL] [Abstract][Full Text] [Related]
9. Investigation of the existence and biological role of L-arginine/nitric oxide pathway in human platelets by spin-trapping/EPR studies.
Prónai L; Ichimori K; Nozaki H; Nakazawa H; Okino H; Carmichael AJ; Arroyo CM
Eur J Biochem; 1991 Dec; 202(3):923-30. PubMed ID: 1662618
[TBL] [Abstract][Full Text] [Related]
10. Identification of a specific transport system for L-arginine in human platelets.
Vasta V; Meacci E; Farnararo M; Bruni P
Biochem Biophys Res Commun; 1995 Jan; 206(3):878-84. PubMed ID: 7832800
[TBL] [Abstract][Full Text] [Related]
11. Nitric oxide and platelet energy metabolism.
Tomasiak M; Stelmach H; Rusak T; Wysocka J
Acta Biochim Pol; 2004; 51(3):789-803. PubMed ID: 15448739
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of human platelet reactivity by endothelium-derived relaxing factor from human umbilical vein endothelial cells in suspension: blockade of aggregation and secretion by an aspirin-insensitive mechanism.
Broekman MJ; Eiroa AM; Marcus AJ
Blood; 1991 Aug; 78(4):1033-40. PubMed ID: 1868238
[TBL] [Abstract][Full Text] [Related]
13. Variable effects of L-arginine analogs on L-arginine-nitric oxide pathway in human neutrophils and platelets may relate to different nitric oxide synthase isoforms.
Chen LY; Mehta JL
J Pharmacol Exp Ther; 1996 Jan; 276(1):253-7. PubMed ID: 8558439
[TBL] [Abstract][Full Text] [Related]
14. The L-arginine/NO pathway in the early phases of platelet stimulation by collagen.
Leoncini G; Bruzzese D; Signorello MG
Biochem Pharmacol; 2005 Jan; 69(2):289-96. PubMed ID: 15627481
[TBL] [Abstract][Full Text] [Related]
15. Neither endogenous nor inhaled nitric oxide influences the function of circulating platelets in healthy volunteers.
Albert J; Wall n NH; Li N; Frostell C; Hjemdahl P
Clin Sci (Lond); 1999 Sep; 97(3):345-53. PubMed ID: 10464060
[TBL] [Abstract][Full Text] [Related]
16. Endogenous nitric oxide acts as a natural antithrombotic agent in vivo by inhibiting platelet aggregation in the pulmonary vasculature.
Emerson M; Momi S; Paul W; Alberti PF; Page C; Gresele P
Thromb Haemost; 1999 Jun; 81(6):961-6. PubMed ID: 10404776
[TBL] [Abstract][Full Text] [Related]
17. Homocysteine-induced inhibition of nitric oxide production in platelets: a study on healthy and diabetic subjects.
Mutus B; Rabini RA; Staffolani R; Ricciotti R; Fumelli P; Moretti N; Martarelli D; Mazzanti L
Diabetologia; 2001 Aug; 44(8):979-82. PubMed ID: 11484074
[TBL] [Abstract][Full Text] [Related]
18. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation.
Radomski MW; Palmer RM; Moncada S
Proc Natl Acad Sci U S A; 1990 Jul; 87(13):5193-7. PubMed ID: 1695013
[TBL] [Abstract][Full Text] [Related]
19. Rat mast cells synthesize a nitric oxide like-factor which modulates the release of histamine.
Masini E; Salvemini D; Pistelli A; Mannaioni PF; Vane JR
Agents Actions; 1991 May; 33(1-2):61-3. PubMed ID: 1716838
[TBL] [Abstract][Full Text] [Related]
20. Human colorectal adenocarcinoma cells: differential nitric oxide synthesis determines their ability to aggregate platelets.
Radomski MW; Jenkins DC; Holmes L; Moncada S
Cancer Res; 1991 Nov; 51(22):6073-8. PubMed ID: 1718593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
